Redmile Group, LLC Jounce Therapeutics, Inc. Transaction History

Redmile Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $847,784 - $1.26 Million	-254,590 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$3.43 - $6.87 $6,458 - $12,936	-1,883 Reduced 0.73%	254,590 $1.58 Million
Q4 2018 Feb 14, 2019	SELL	$2.69 - $6.71 $454,453 - $1.13 Million	-168,942 Reduced 39.71%	256,473 $864,000
Q3 2018 Nov 14, 2018	SELL	$6.5 - $8.37 $5.13 Million - $6.61 Million	-789,178 Reduced 64.97%	425,415 $2.77 Million
Q2 2018 Aug 14, 2018	BUY	$7.27 - $21.88 $234,094 - $704,536	32,200 Added 2.72%	1,214,593 $9.3 Million
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $2.71 Million - $5.74 Million	202,000 Added 20.6%	1,182,393 $0
Q4 2017 Feb 14, 2018	BUY	$12.52 - $17.82 $310,433 - $441,846	24,795 Added 2.59%	980,393 $12.5 Million
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $10.7 Million - $16.2 Million	955,598	955,598 $14.9 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.